Budget Amount *help |
¥17,290,000 (Direct Cost: ¥13,300,000、Indirect Cost: ¥3,990,000)
Fiscal Year 2022: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2021: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2020: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
Outline of Final Research Achievements |
In this study, we aimed to develop a human ADME model with reduced effects of mouse plasma proteins by generating humanized liver chimeric mice deficient in two major plasma proteins, Albumin (Alb) and Alpha-1-acid Glycoprotein 1 (Agp1). The expression of human drug metabolism-related genes in the liver of Alb/Agp1 double KO humanized liver chimeric mice was similar to that of traditional humanized liver chimeric mice, suggesting that the effect of these plasma protein deficiencies was limited. In this model, there was a large discrepancy between the predicted and measured drug metabolism clearance value for Diazepam in humans. However, the predicted value of drug metabolism clearance in humans for Ketoprofen and UCN-01 provided by Alb/Agp1 double KO humanized liver chimeric mice was similar to the measured value in humans.
|